With Neogene buy and a CAR-T in the clinic, AstraZeneca builds up cell therapy 'library'

With the acquisition of Neogene Therapeutics this week and a CAR-T now in phase 1 courtesy of a Chinese partnership, AstraZeneca hopes to add the first volumes to a planned “library” of off-the-shelf cell therapies.